Verapamil Boosts Melphalan Effectiveness in Mice
Author Information
Author(s): B.A. Robinson, R.D. Clutterbuck, J.L. Millar, T.J. McElwain
Primary Institution: Royal Marsden Hospital and Institute of Cancer Research
Hypothesis
Does verapamil enhance the cytotoxicity and cellular uptake of melphalan in murine fibrosarcoma and bone marrow?
Conclusion
Verapamil significantly increases the effectiveness of melphalan by enhancing its uptake and prolonging tumor growth delay in mice.
Supporting Evidence
- Verapamil increased the growth delay of tumors treated with melphalan from 6 days to 16 days.
- Blood levels of melphalan were significantly higher when administered with verapamil.
- Verapamil enhanced melphalan cytotoxicity to murine bone marrow in vitro.
Takeaway
Verapamil helps a cancer drug called melphalan work better in mice by making it easier for the drug to get into the cancer cells.
Methodology
CBA mice were treated with melphalan and verapamil, and tumor growth delay and drug uptake were measured.
Limitations
The study was conducted only in mice, and results may not directly translate to humans.
Participant Demographics
CBA/ca mice, both male and female, aged 12-24 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website